RecruitingNot ApplicableNCT06637462

A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer

DISCRN in Rectal Cancer: DISseCting Response to Neoadjuvant Therapy in Rectal Cancer

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

30 participants

Start Date

Oct 9, 2024

Study Type

INTERVENTIONAL

Conditions

Rectal Cancer Adenocarcinoma of the Rectum

Summary

The purpose of the study is to learn more about how the body responds to standard treatment (chemoradiation and chemotherapy). The study will use the results of testing down on participants' blook, tissue, and scans to learn more about how people with rectal cancer respond to chemoradiation and chemotherapy treatment and if it is useful for predicting whether a person's cancer get better, gets worse, or stats the same after treatment.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

years of age or older on day of signing informed consent.
Have a histologically confirmed diagnosis of invasive adenocarcinoma of the rectum with no known mismatch repair deficiency or Her2 amplification.
Eligible for and plan to initiate standard-of-care therapy with any of the following regimens:
Induction fluoropyrimidine (capecitabine \[preferred\] or 5-FU) based chemoradiation
With plan for consolidative CAPEOX, FOLFOX, or FOLIRINOX
Woman with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use an effective contraceptive method. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. Reliable contraception should be used from the time of screening and must be continued throughout the duration of treatment as per standard of care.

Exclusion Criteria6

Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
Patients with prior external beam radiation therapy to the pelvis or brachytherapy seed implantation of the prostate.
Patients who are pregnant or breastfeeding.
Men or women not using effective contraception.
Patients with a contraindication to MR imaging.
Patients on blood thinners prohibiting endoluminal tumor biopsies.